Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
Status:
Recruiting
Trial end date:
2022-08-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the ability of a repeated high-frequency
site-based computerized cognitive assessment to evaluate the potential treatment effects of
donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment
(MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average
percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points
in participants receiving donepezil compared with participants receiving placebo.